FPH - Fisher Paykel Healthcare.

[Rawz]

W69 will let you know AFTER he's locked and loaded

true.. i forget the sums W69 deals with moves the market

[IAK]

Some rumblings at FPH? https://businessdesk.co.nz/article/b...ular-workplace

[alokdhir]

Looks like someone got left out of this uptrend and they want another chance ...maybe Mr B ....lol

[alokdhir]

March exports data showed 15% increase on last March exports ....

Overall FPH on track to report little better then expected revenues but still its fully priced imo

We may have run too much too soon ...results may lead to disappointment ...

[limmy]

Result expected tomorrow, 26th May

[alokdhir]

Results are pretty much well forecast ...outlook ahead will be key ...Easy to disappoint but now SP has corrected from heady $ 28 levels ...

Fingers crossed

[alokdhir]

Guidance resumes ...Growth resumes ...Good for stock

[Rawz]

Guidance resumes ...Growth resumes ...Good for stock

https://www.nzx.com/announcements/412082

Overview of key results for the second half of the 2023 financial year
• 14% growth in operating revenue to $890.5 million, 12% growth in constant currency.
• Net profit after tax of $154.4 million, a decline of 0.5% or 3% in constant currency.
• 9% growth in Hospital operating revenue to $584.8 million, 7% growth in constant currency.
• 13% constant currency revenue growth for new applications consumables; i.e. products used in noninvasive ventilation, Optiflow nasal high flow therapy and surgical applications, accounting for 72% of Hospital consumables revenue.
• 25% growth in Homecare operating revenue to $303.9 million, 22% growth in constant currency.
• 28% growth in OSA masks revenue, or 24% growth in constant currency.

Overview of key results for the 2023 financial year
• 34% decline in net profit after tax to $250.3 million, 39% decline in constant currency.
• 6% decline in operating revenue to $1.58 billion, 9% decline in constant currency.
• 15% decline in Hospital operating revenue to $1.02 billion, 18% decline in constant currency.
• 6% constant currency revenue decline for new applications consumables.
• 18% growth in Homecare operating revenue to $553.8 million, 13% growth in constant currency.
• Investment in R&D was 11% of revenue, or $174.3 million.
• 2% increase in final dividend to 23.0 cps (2022: 22.5 cps).
• 3% increase in total dividends for the financial year to 40.5 cps (2022: 39.5 cps).

[winner69]

Guidance resumes ...Growth resumes ...Good for stock

Single digit revenue growth expected ….. trading on a PE of 60 ….hmmmmm

[Ggcc]

Single digit revenue growth expected ….. trading on a PE of 60 ….hmmmmm

For longterm holders it will only rise over time and this is just a short term blip, but for traders a song by Kaleo comes to mind. “Way down we go” of course I could be wrong….